Table 3.
Demographic, clinical, cognitive, and neuroimaging characteristics in male and female APOE ε4 carriers and non-carriers
| PSEN1 Mutation Carriers (n=167) |
Non-carriers (n=75) |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Males | Females | Males | Females | |||||||||
| APOE ε4+ (n=18) |
APOE ε4− (n=48) |
p | APOE ε4+ (n=18) |
APOE ε4− (n=83) |
p | APOE ε4+ (n=6) |
APOE ε4− (n=19) |
p | APOE ε4+ (n=11) |
APOE ε4− (n=39) |
p | |
| Age | 37.2±4.9 | 37.9±6.2 | 0.70 | 35.8±4.4 | 35.9±5.3 | 0.91 | 43.3±6.9 | 40.9±6.1 | 0.42 | 41.6±5.0 | 42.4±6.4 | 0.68 |
| Education (years) | 8.89±3.16 | 8.79±4.51 | 0.93 | 9.72±3.08 | 8.52±4.20 | 0.25 | 8.67±4.93 | 8.21±4.83 | 0.84 | 9.55±3.67 | 8.31±4.39 | 0.40 |
| MMSE | 28.83±1.34 | 28.79±1.09 | 0.90 | 29.33±1.09 | 28.71±1.60 | 0.12 | 29.50±0.55 | 29.21±0.79 | 0.41 | 29.64±0.67 | 29.03±1.11 | 0.09 |
| FDG Precuneus | 2.35±0.11 | 2.43±0.16 | 0.83 | 2.39±0.13 | 2.43±0.14 | 0.85 | 2.59±0.07 | 2.45±0.15 | 0.009 | 2.53±0.11 | 2.46±0.13 | 0.95 |
| Hippocampal Volume × 10 3 | 5.7±0.6 | 5.8±0.5 | 0.67 | 5.8±0.4 | 5.9±0.4 | 0.43 | 6.1±0.4 | 5.7±0.4 | 0.07 | 6.0±0.5 | 5.9±0.4 | 0.25 |
| Amyloid Burden | 0.88±0.17 | 0.87±0.13 | 0.90 | 0.88±0.16 | 0.83±0.13 | 0.14 | 0.65±0.04 | 0.63±0.04 | 0.32 | 0.65±0.02 | 0.65±0.03 | 0.67 |
| CERAD Word List Learning | 18.33±4.41 | 19.52±4.54 | 0.34 | 20.72±4.01 | 20.43±4.56 | 0.97 | 21.67±2.42 | 20.53±4.31 | 0.55 | 22.09±4.23 | 21.08±4.03 | 0.47 |
| CERAD Word List Delayed Recall | 5.44±2.77 | 6.77±2.17 | 0.04 | 7.28±1.78 | 7.20±2.08 | 0.88 | 7.33±2.81 | 7.26±2.02 | 0.95 | 8.18±1.94 | 7.82±1.59 | 0.53 |
Note. APOE ε4+/−, APOE genotype was coded as positive or negative for presence of an ε4 allele. Abbreviations: MMSE, Mental Status Exam; FDG, 18F-fludeoxyglucose (FDG) positron emission tomography; CERAD, Consortium to Establish a Registry for AD.